Therapeutic Range for Sertraline
The therapeutic plasma concentration range for sertraline is 10-50 ng/mL, measured as trough levels at steady state 1.
Evidence Quality and Recommendation Level
The AGNP-TDM Expert Group Consensus Guidelines classify sertraline with a Level 3 recommendation for therapeutic drug monitoring, meaning TDM is "useful" 1. This indicates:
- The suggested therapeutic range represents plasma concentrations at effective doses obtained from steady-state pharmacokinetic studies
- Clinical data comes from retrospective TDM analysis and clinical experience rather than prospective controlled trials
- TDM is useful to verify plasma concentrations are plausible for a given dose and may help optimize response in nonresponders with low concentrations 1
Key Clinical Context
When to Measure
- Collect blood samples at trough levels (just before next dose) at steady state 1
- Steady state is achieved after approximately one week of once-daily dosing (based on 26-hour half-life) 2
Specific Clinical Situations Where TDM is Most Valuable
- Suspected noncompliance
- Lack of clinical response despite adequate dosing
- Adverse effects at therapeutic doses
- Suspected drug interactions (especially with CYP2D6/CYP2C19 inhibitors)
- Elderly patients (who show ~40% lower clearance) 2
- Pediatric patients (who metabolize sertraline ~22% more efficiently than adults) 2
- Patients with hepatic impairment (3-fold greater exposure in mild liver disease) 2
- Pharmacogenetic poor or ultrarapid metabolizers 3
Important Caveats
Limited Concentration-Effect Relationship
Unlike tricyclic antidepressants with well-established therapeutic windows, sertraline does not have a clearly demonstrated linear plasma concentration-clinical effectiveness relationship 1. One study of 21 patients found no correlation between plasma levels (range 2.82-112.20 ng/mL) and clinical improvement or side effects 4.
Recent Pediatric Data
A 2026 study in pediatric patients with anxiety disorders found an interquartile range of 27.85-57.91 ng/mL associated with favorable efficacy-safety balance 5. The same study reported that 25-54 ng/mL represents the 25th-75th percentile in children and adolescents 6, which aligns closely with the adult guideline range of 10-50 ng/mL.
Metabolite Considerations
N-desmethylsertraline (the primary metabolite) is substantially less active than sertraline and has a longer half-life (62-104 hours) 2. The guidelines recommend monitoring sertraline alone, not the metabolite, for therapeutic purposes 1.
Practical Application
Use the 10-50 ng/mL range as a reference point rather than an absolute target. If levels are:
- Below 10 ng/mL: Consider dose increase, assess compliance, or evaluate for ultrarapid metabolism
- Within 10-50 ng/mL: Appropriate range for most patients
- Above 50 ng/mL: Consider dose reduction if adverse effects present, or evaluate for drug interactions/poor metabolism
The lack of strong concentration-effect data means clinical response and tolerability should guide treatment more than plasma levels alone, but TDM remains valuable for troubleshooting treatment failures and managing complex cases 1, 7.